Trump-Era NIH Cuts Leave Scientists Facing Lab Closures and Broken Trust

The past year has brought unprecedented uncertainty to the world of biomedical research, and for many young scientists, that uncertainty is translating into a difficult question: is a career in science still viable? A new nationwide survey of nearly 1,000 researchers funded by the National Institutes of Health reveals a growing sense of unease, with labs shutting down and early-career scientists facing an increasingly precarious future. Even as some Trump administration policies have been reversed, the damage to trust and the disruption to research are proving difficult to overcome.

The challenges stem from a series of funding cuts, delays, and policy changes implemented over the past year. These aren’t simply budgetary adjustments; they represent a fundamental shift in how the federal government approaches scientific inquiry. The impact is being felt acutely by those just beginning their careers, who face a landscape far less stable than the one their predecessors encountered. The situation is prompting a reevaluation of career paths, with some talented individuals considering leaving science altogether.

A Grant Terminated, a Future Uncertain

Minoli Perera, a researcher at Northwestern University, exemplifies this growing anxiety. For decades, her function has focused on understanding how African ancestry influences responses to medication. She received an NIH grant in 2024 to study responses to clopidogrel, a common heart attack and stroke prevention drug. Previous research indicated that genetic mutations affected the drug’s efficacy, but these studies largely focused on individuals of European descent. Perera’s study, conducted in Puerto Rico, aimed to address this gap by including a diverse population with varying levels of African, European, and indigenous ancestry. Details of the grant can be found on the NIH Reporter website.

Though, the grant was terminated last year, with NIH citing concerns that it was based on non-scientific categories promoting diversity, equity, and inclusion. Perera strongly disputes this, arguing that her study focused on genomic data, not racial categories. The loss of $500,000 in funding has jeopardized her lab and the work of her team. She’s now facing the possibility of shutting down her lab altogether, as institutional support will run out at the end of August. The situation highlights a broader concern: the difficulty of navigating grant applications in an environment where seemingly innocuous language can trigger scrutiny.

Perera describes feeling pressured to avoid certain phrases in her grant applications, resorting to vague terminology to avoid raising red flags with NIH reviewers. This compromises the clarity and specificity that are hallmarks of good science. She openly questions whether she would pursue a faculty position today, given the current climate. “Not in the United States,” she states.

Derailed Ambition: A Personal Connection to Research

Iris Smith’s story is another illustration of the challenges facing young scientists. She was on the cusp of launching a lab at the Cleveland Clinic to study endometriosis, a chronic and often debilitating condition that she herself experiences. Smith’s journey to a research career was unconventional; she entered college at 26 after working in auditing and marketing, driven by a desire to understand her own illness. She received a prestigious Pathway to Independence award (K99/R00) from NIH in 2020, providing crucial support for her transition to an independent scientist.

However, that funding was terminated last year as part of the administration’s efforts to eliminate diversity, equity, and inclusion initiatives. The award came through the MOSAIC program, designed to diversify the biomedical workforce. STAT News reported on the impact of these cuts in December 2025. Without funding, the Cleveland Clinic will not be renewing her employment contract. Smith is now searching for alternative funding and job opportunities, but the landscape is increasingly competitive.

Smith’s experience underscores the personal toll of these funding disruptions. Her research wasn’t simply an academic pursuit; it was driven by a deep personal connection to the disease she was studying. Despite the setbacks, she remains committed to advocating for endometriosis patients, regardless of her future career path.

Data in Limbo: The Cost of Ideological Cuts

Carl Latkin, a behavioral scientist at Johns Hopkins University, faces a different, but equally frustrating, challenge. His five-year study examining the impact of environmental stressors on HIV patients was cut short when his NIH funding was terminated. Latkin has studied the social and behavioral factors influencing HIV for nearly three decades, with consistent NIH support. He has a long track record of mentoring young scientists.

Now, data collected from around 500 participants in the Baltimore area sits unanalyzed, lacking the resources for processing and interpretation. Latkin argues that the cuts, justified as targeting “waste, fraud, and abuse,” are actually hindering scientific progress. He emphasizes the irony of halting research aimed at improving public health while simultaneously claiming to reduce waste. He also expresses concern about the message these cuts send to aspiring scientists, questioning whether he can ethically encourage them to pursue careers in NIH-funded research.

Latkin’s experience highlights a broader issue: the disruption of long-term research projects and the loss of valuable data. The time and effort invested in collecting this data are effectively wasted, and the potential insights remain unrealized.

These individual stories, drawn from interviews with 30 researchers, paint a stark picture of the challenges facing the biomedical research community. The cuts aren’t simply numbers on a spreadsheet; they represent broken trust, derailed careers, and lost opportunities to advance scientific knowledge. The long-term consequences of this disruption remain to be seen, but the immediate impact is clear: a growing sense of uncertainty and a reevaluation of the future of scientific research in the United States.

The National Institutes of Health has not yet released a comprehensive plan to address these concerns. However, ongoing legal challenges to the grant terminations and increased scrutiny from Congress may prompt a reassessment of current policies. Researchers are closely watching for any signs of a shift in direction, but for many, the damage has already been done. The process of rebuilding trust and restoring stability to the nation’s research enterprise will likely be a long and arduous one.